List of Antibodies Companies in Switzerland - 48

Abologix is a biopharmaceutical company based in Geneva, Switzerland. The company is a spin out from the laboratories of Prof. Beat Imhof and Thomas Matthes at the University of Geneva and the Geneva University Hospitals. The company is developing two monoclonal antibodies that selectively block two novel pharmacological targets. Several oncological medical indications are being pursued.

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.

ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).

A start up based in Switzerland that develops biologics to modulate the functions of cytokines and provide substantial therapeutic benefits to cancer patients.

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Baliopharm was acquired by Promethera Biosciences on April 10, 2018. Baliopharm was founded in 2006 as Celonic AG, a service company for the contract development and manufacturing of biopharmaceutical compounds, based on the...

Beech Biotech is unlocking novel biology to create breakthrough treatments for preeclampsia and other complications of pregnancy. Each year, preeclampsia causes the deaths of 70,000 mothers, 500,000 babies worldwide. Beyond that, long-term health consequences affect 300 million surviving mothers and their preterm infants. A key unmet need are medicines that treat only the mother without exposing the fetus to additional risk. We are addressing this need by developing “Mother only” monoclonals, achieved by a patented modification that blocks antibodies from crossing the placenta. Our lead asset, MOm303, binds and eliminates maternal sFlt-1, a known cause of vascular breakdown in preeclampsia, and releases placental growth factor, thus restoring the healthy balance of these factors. This has the potential to prolong pregnancy and reduce the consequences of preterm birth

Critical Raw Materials and Services for Diagnostics, Vaccines and Pharmaceuticals. Where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. Biosynth's mission is to supply critical raw materials and services to the pharmaceutical and diagnostic industries. Biosynth strives to de-risk its customer's supply chains. Our expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Biosynth is a life sciences reagents, custom synthesis and manufacturing services company. We are by scientists, for scientists, securing supply chains with consistent quality, across the globe. We manufacture and source a vast range of chemical and biochemical products, and take pride in delivering products that others cannot. We are experts in complex chemistry, peptides and key biological raw materials. We provide a full range of products and services to support life science research and development, with more than a million products in our research catalog and hundreds of complex manufacturing service projects. The trusted supplier, manufacturer and partner for the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. We produce chemicals on the milligram to ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale. Biosynth's services and products include enzyme development and biocatalysis, reagents for in vitro diagnostics and bioconjugation chemistry. Biosynth is owned, among others by KKR, Ampersand and Senior Management.

Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical conjugation technology, any therapeutic antibody at any stage of development can be conjugated with Bright Peak’s cytokine payloads of choice, eliminating the current complexities of antibody engineering and cell line development. Bright Peak’s team works with a passion for innovation and bold science. We are an international research-driven organization dedicated to discovering and developing cutting edge therapies that will make a difference in the lives of patients. We aim to create a vibrant and international corporate culture and are currently hiring in our Basel, Switzerland and Southern California locations.

CARBOGEN AMCIS leverages its world-class chemistry skills to provide seamless drug substance, drug products development and commercialization services for leading pharmaceutical and biopharmaceutical companies. We help customers create a better world by becoming the partner of choice thanks to our innovative solutions. We offer an array of integrated and customized services operating in a fully cGMP-compliant infrastructure, including dedicated Highly Potent API facilities and a clean room for Antibody Drug Conjugates. Beyond our services, we also provide high-quality Cholesterol and Vitamin D analogs. CARBOGEN AMCIS is owned by Dishman Carbogen Amcis Limited, (India). Learn more about us: www.carbogen-amcis.com

CDR-Life is a biotherapeutics company developing novel therapies harnessing the power of the immune system. Today’s cancer immunotherapies are powerful but are not tumor targeted, which compromises both efficacy and safety. We are developing a next generation of highly tumor-selective immunotherapies to truly empower the immune system to eradicate malignant cells without the off-tumor-related limitations of current immunotherapies. CDR-Life has developed the unique M-gager® technology to generate MHC-specific antibody-based T cell engagers that target highly tumor-specific intracellular antigens with unparalleled specificity. Our dual-MHC binding molecule format based on antibody fragments has the promise of developing new immunotherapies with high tumor cell killing potency, longer duration of effect, and lower risk of immune-related adverse effects. CDR-Life is advancing a growing portfolio of novel and highly tumor-selective immunotherapies based on the M-gager® technology.

With more than 45 years’ experience in the pharmaceutical industry, Swiss-based CERBIOS is specialized in the manufacturing of Generic APIs&HPAPIs alongside with finished formulations based on its own probiotic strain and exclusive CDMO services for HPAPIs, ADCs and recombinant proteins. 𝐏𝐡𝐚𝐫𝐦𝐚 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐬 Cerbios portfolio covers a wide range of drug substances including reduced folates such as Calcium Folinate (Leucovorin Calcium), Calcium Levofolinate, Folinic Acid, 5-Methyl-Tetrahydrofolic Acid Calcium Salt, Sodium Folinate, as well as other folates manufactured exclusively for customers. Starting from 1993 Cerbios specialized further in the commercial manufacturing of HPAPIs, with a particular focus on Vitamin D Derivatives, (analogues). Cerbios has also a long standing experience in the probiotics field. For more than 40 years Cerbios produces its finished pharmaceutical drug based on proprietary strain Enterococcus faecium SF68®, for treatment of diarrhea and dysbiosis by antibiotics. Due to the unique characteristics of SF68®, Cerbios recently marketed two new Food Supplements for the management of ACNE & Seborrheic dermatitis and to boost immune response; other new formulations/application are in development phase. 𝐂𝐃𝐌𝐎 Services Cerbios is the ideal partner from clinical to commercial supply of API, HPAPIs, Payloads, ADCs, Proteins and Antibodies. Services offered include Process & Analytical Development, Scale-up and Clinical Supply, Industrial Validation, Commercial Supply, Full CMC Regulatory Support. Within its ADC dedicated division -Proveo (TM)- Cerbios has leveraged the combined experience in Payloads and recombinant proteins to offer an end-to-end solution for Antibody Drug Conjugates (ADCs). 𝐀𝐧𝐢𝐦𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 Products CERBIOS offers a range of products for animal feed or veterinary application including probiotic feed additives Cernivet® LBC G35, Cernivet® LBC ME5 PET, Cernivet® LBC M10, Cernivet® LBC M20 plus.

Cimeio Therapeutics is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs for patients with serious and life-threatening diseases. Cimeio’s proprietary technology platform is based on the discovery of protein variants, which when edited into cells allow them to maintain full function while resisting paired immunotherapy depletion. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.

CIS Pharma is an independent pharmaceutical research and development company that was established in 1952. It is based in the Basel Area, Switzerland and focuses on developing next-gen immuno-conjugates, ADCs, and radioligand. The company also specializes in novel contact lens coating technology.

CovalX has been established as the leader in characterizing protein interactions by mass spectrometry. Providing Innovative Technologies and Exclusive Services, CovalX has been doing business with world-renowned Universities, therapeutic companies, and most major pharmaceutical companies worldwide for many years. CovalX AG developed a unique protocol for measuring intact protein complexes using MALDI mass spectrometry. CovalX both sells the tools and/or services for High-Mass MALDI protein-protein interaction analysis. The main applications involve: • epitope mapping (both conformational or linear) • characterizing aggregates from biotherapeutic drugs • analyzing antibody-antigen interactions • rapid characterization of any protein complexes (stoichiometry, inhibition, etc) CovalX also has flexibility and provides services for characterizing any large macro molecules such as PEGylated proteins or polymers. CovalX has recently restructured by moving some of its hardware support facilities and US sales and marketing into the US and establishing an official subsidiary in the Boston area.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!

Elthera AG is a Swiss biopharmaceutical start-up company bringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs using a personalized health care approach. Elthera AG is developing antibodies against a novel target whose expression is strongly correlated with an aggressive tumor phenotype and poor prognosis in various types of cancer. By combining targeted therapies with companion diagnostics, Elthera AG is aiming at providing new personalized treatment options for patients with the most aggressive malignancies

For more than 45 years, Enzo Biochem has been a leader in innovation and product development to support a diverse range of needs in biomedical research and healthcare. With a comprehensive portfolio of 20,000 high-quality products including antibodies, genomic probes, assays, biochemicals, and proteins, Enzo supports the work of academic research centers and industry partners who are shaping the future of healthcare around the world. The company’s proprietary products and technologies play central roles in all areas of translational research and drug development, including genomic analysis, protein analysis, cellular analysis, tissue analysis, and small molecule chemistry. Enzo Biochem has a broad and deep intellectual property port-folio, with patent coverage across a number of key enabling technologies.

​evitria is specialized in CHO-based transient expression of antibodies (including bispecific and fusion antibodies). With a track record of more than 120,000 successful antibody production runs for our clients, we can offer fast and reliable project execution at high quality standards (all production facilities in Switzerland). You can benefit from our expertise and unique focus when looking to entrust a partner with your complete antibody production or to manage capacity bottlenecks with single projects.

Looking for a trusted partner in the development of cell lines and manufacturing processes? Look no further. With over 20 years of experience, we specialize in high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). We have a proven track record of expressing all types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, cytokines, and more. Our team of scientists is ready to support your project from start to finish, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. At our company, we pride ourselves on our commitment to quality and customer satisfaction. Contact us today to see how we can help you achieve your goals and be your trusted partner in cell line and process development.

Granite Bio is a biotechnology company developing first-in-class antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions. Granite is backed by leading healthcare venture firms including Versant Ventures, Novartis Venture Fund, Forbion and Sanofi Ventures.

At Immitra Bio, we are pioneering a next-generation gene therapy platform, harnessing Hematopoietic Stem Cells and their downstream cell lineages, such as red blood cells as living, in-vivo biotherapeutic protein factories. The CRISPR-Cas-based cell and gene therapy platform we are developing is versatile and promises to be easily reprogrammable.

ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).

Kenta Biotech is focusing on the discovery and development of innovative, fully human monoclonal antibodies for the treatment of life-threatening hospital infections such as hospital acquired pneumonia. In spite of antibiotic treatment a significant number of patients still die from the infection they acquired at the hospital. Kenta is addressing this significant unmet medical need and has established antigen screening and functional assays for several targets. Kenta's proprietary MabIgX technology combines the advantages of classical hybridoma technology with a unique specific heteromyeloma fusion cell line for the generation and selection of fully human monoclonal antibodies (MAbs). The MabIgX technology allows to harness the most effective antibodies generated by immunocompetent individuals through the isolating and propagation of antigen-specific human B-cells isolated from healthy individuals, actively immunized individuals or from individuals who have successfully defeated an infection caused by the target pathogen. After selection these highly antigen-specific human B-cells are immortalized employing a specific heteromyeloma cell line as fusion partner, which generates stable hybridomas for large scale manufacturing of target specific fully human MAbs. The MabIgX technology does not require any genetic engineering steps or expression systems protected by third party intellectual property rights. The proprietary MabIgX technology platform enables the generation of natural human MAbs with expected superior safety and efficacy profiles. Kenta Biotech currently has one product candidate in clinical development and several product candidates in preclinical development. The lead compound, KBPA 101, is in early Phase II clinical trials in hospital-acquired pneumonia. In 2006, KBPA 101 has received Orphan Drug Status from the EMEA and FDA.

NovImmune has successfully divested EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019. NovImmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand as: “Light Chain Bioscience – A brand of Novimmune SA”. The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function. A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop. Thus far, NovImmune has advanced seven drug candidates to treat a range of conditions. The Company’s pipeline is a balance of preclinical and clinical candidates for validated and novel targets. NovImmune has established a next-generation antibody drug discovery platform that includes novel bispecific antibody drug capabilities - the simple, stable and smart kappa-lambda-body™. In 2009, NovImmune received the European Biotechnica Award. In 2010, NovImmune entered a partnership with Genentech to advance the Company’s anti-IL17 drug candidate. In addition to pursuing additional drug discovery, development and commercialization partnerships, the Company plans to bring selected drugs to market for focused applications.

Linkster is a swiss-based precision medicine company focusing on multi-specific antibodies and tissue-specific delivery. The company creates next generation targeted therapeutics through its Flycode® platform for high-throughput cellular and in vivo antibody engineering. Linkster has entered into several agreements with pharmaceutical and biotech companies and is actively seeking further partnerships for the co-development of innovative therapeutic products.

Lunaphore Technologies S.A., a Bio-Techne brand, is a Swiss-based life sciences company founded in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies.

Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies, neurodegenerative diseases, and inflammation. The firm’s strength is rooted in extensive and successful experiences in both the pharmaceutical and biotech industry, along with a solid academic track record.

MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Our vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease. Our success in research and access & product management comes from our extensive partnership network of over 375 pharmaceutical, academic and endemic-country partners in 50 countries. www.mmv.org www.facebook.com/medicinesformalaria www.twitter.com/medsformalaria www.youtube.com/user/MMVmeds4malaria http://plus.google.com/+mmvorgmedsformalaria

Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company’s lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients. Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid structure biology. The Company has a partnership in place with Ono Pharmaceutical for two oncology targets. Underpinning MTx’s core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.

MoonLake has a portfolio of therapeutic programs based on the phase 3-ready Nanobody® Sonelokimab (SLK, M1095/ALX-0761), a biologic molecule potentially capable of driving disease modification in dermatology and rheumatology patients. A single-domain antibody (sdAb), also known as a Nanobody®, is an antibody fragment consisting of a single monomeric variable antibody domain. Like antibodies, Nanobodies® are able to bind selectively to a specific antigen with high affinity.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune discovered aducanumab for Alzheimer's disease together with a team of researchers at the University of Zurich and licensed it to Biogen. Neurimmune's Reverse Translational Medicine technology platform translates the genetic information from human white blood cells into selective high-affinity antibody drug candidates. Besides aducanumab, Neurimmune discovered cinpanemab for Parkinson's disease, the anti-tau antibody BIIB076 for Alzheimer's disease, the anti-miSOD1 antibody AP-101 for amyotrophic lateral sclerosis, and the anti-ATTR antibody NI006 for cardiomyopathy. These programs are currently evaluated in clinical trials.

NovaGo’s fully human monoclonal antibodies have the potential to become a safe and effective treatment in central nervous system indications. NovaGo’s proprietary antibodies block the function of Nogo-A, one of the most potent and well-studied vascular and nerve growth inhibitors.

Novartis is reimagining medicine to improve and extend people’s lives. We deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. About 106,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.

Numab Therapeutics is an oncology-focused biopharmaceutical company based in the Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH™ technology platform we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes.

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors. For more information, please visit: www.oculis.com

Onena Medicines is a biopharmaceutical company with a pipeline of first-in-class antibody medicines to treat recurrent and metastatic cancers and selected rare diseases. Onena’s drugs neutralize a new class of secreted ancient growth factors, conserved across species, called Dual SMAD Inhibiting Proteins (DSIPs), that program cancer cells to grow and resist chemotherapy. Blocking DSIPs, as demonstrated in-vivo by Onena, simultaneously reactivates physiological TGF-β and BMP signaling and elicits cellular reprogramming, resulting in cancer cells accepting environmental cell death signals from BMPs and Activins. Onena has developed a proprietary AI-centric antibody drug discovery platform that rapidly generates anti-DSIP neutralizing antibodies, even when no crystal structure of the antigen is available. OMED-101, Onena’s anti-LEFTY1/2 lead candidate antibody, has demonstrated broad efficacy against breast, colorectal and brain cancers without observable toxicities in preclinical models. Through its unique platform, Onena Medicines has discovered several DSIPs and aims to advance multiple neutralizing DSIP antibody drugs into clinical development in the next three years.

Quadira Biosciences combines two outstanding cutting-edge technology platforms to complete the development and preclinical studies of ten new Antibody Drug Conjugates (ADCs) within 4 months each. This dramatically extend the previously rather limited commercial lifecycle of antibody drugs. Collectively, the planned ADC portfolio has a market value of $25 billion. The first new anti-HER-2 ADC has already been completed and documented in the last four months and is currently being prepared for licensing.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

With the effective control of infectious diseases in many parts of the world, chronic, often non-communicable diseases have become the single largest cause of death and disability.Treatment of such chronic diseases is expensive and often ineffective. There is therefore a major need for novel treatment modalities to prevent rather than treat chronic diseases and that are available at affordable costs.Inducing long-lived antibody responses by vaccination against endogenous molecules, which are normally targeted by monoclonal antibodies, represents a promising way to tackle this issue.Saiba GmbH uses virally shaped nanoparticles as a scaffold for the generation of tailor-made vaccines. The nanoparticle base of the vaccines tricks the immune system into believing to be under viral attack, causing a strong immune response against the displayed antigen.

ten23 health is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow’s medicines. Our sites in Visp and Basel 🇨🇭 support our clients in developing differentiated, stable, usable, and safe injectable treatments for patients. More about us: www.ten23.health

We are a successful and leading international company in the field of in-vitro diagnostics. With projects in over 40 countries, we set standards in medical diagnostics. Our success is based on our high-quality products and a global network of experts. Our team of 50 workforce places great emphasis on teamwork and open communication.

Leading with purpose. Every day. “Ultragenyx was founded to advance innovative medicines for rare and ultrarare diseases that have never been treated before. We are delivering transformative therapies across multiple indications, and we have one of the most robust and diverse clinical pipelines in rare disease. Our focus is on doing the right things for patients both during development and commercialization to deliver on the promise of these therapies in a way that's meaningful for rare disease communities.” Emil D. Kakkis, M.D., Ph.D. Chief Executive Officer and President We have an inclusive culture of value and respect. Ultragenyx brings novel products to those living with rare and ultrarare diseases with a focus on debilitating genetic diseases. Founded in 2010, we have rapidly built a diverse portfolio of approved therapies and products aimed at diseases with a high unmet medical need for which many have no approved therapies. It takes courage, care, talent, and dedication to make a meaningful impact for those living with rare diseases, their families and the rare disease community. We put our people first, so they can take care of the rare disease community. We purposefully cultivate and nurture a dynamic, supportive work environment where we encourage every team member to share their new ideas and help us unlock more possibilities. Our team is made up of exceptional and diverse people with a strong passion and commitment to helping those living with rare diseases. By embracing generosity, curiosity, inclusion, and humility we are constantly learning together—fostering an environment that supports profound growth and fulfillment. If you want to have a meaningful impact, do the best work of your career while having fun and growing professionally and personally, come join our team! Visit our community guidelines at: https://ultragenyx.co/community

Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development and creating novel, long-acting bispecific programs for immunological diseases.

Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making extensive progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation.